Abstracts tagged "Psoriatic arthritis"

Abstract Number: L04 • ACR Convergence 2022
Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno¹, Ananta Paine², Soumyaroop Bhattacharya³, Jeffrey Fox⁴, Ernest Meyer⁵, Brian Isett⁵, Riyue Bao⁶, Tullia Bruno⁶ and Christopher Ritchlin⁷, ¹University of Rochester, Rochester, NY, ²ORNA Tx, Southborough, MA, ³Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, ⁴CMSR, University of Rochester Medical Center, Rochester, NY, ⁵UPMC Hillman Cancer Center, Pittsburgh, PA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of Rochester Medical Center, Rochester, NY
Background/Purpose: A pivotal clinical characteristic of psoriatic arthritis (PsA) is disease manifestations in several domains (skin, entheses, joints, spine) and multiple domain involvement is prevalent,…
Abstract Number: L02 • ACR Convergence 2022
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Christopher Ritchlin¹, Laura Coates², Iain McInnes³, Philip J. Mease⁴, Joseph Merola⁵, Yoshiya Tanaka⁶, Akihiko Asahina⁷, Laure Gossec⁸, Alice Gottlieb⁹, Diamant Thaci¹⁰, Barbara Ink¹¹, Deepak Assudani¹¹, Rajan Bajracharya¹¹, Vish Shende¹¹, Jason Coarse¹² and Robert Landewé¹³, ¹University of Rochester Medical Center, Rochester, NY, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ³College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁵Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁶University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁷Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ⁸Sorbonne Universités, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Hôpital Pitié Salpêtrière, Rheumatology Department, Paris, France, Paris, France, ⁹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹¹UCB Pharma, Slough, United Kingdom, ¹²UCB Pharma, Raleigh, NC, ¹³Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, and Zuyderland MC, Heerlen, Netherlands
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy in joints and…
Abstract Number: 0387 • ACR Convergence 2022
Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity
Marta Ibañez Martinez¹, Sonia Pastor Navarro², Olga Compán Fernández², Belén Miguel Ibáñez², Ana Isabel Turrión Nieves², Susana Gómez Castro¹, Olga Martínez González², Cristina Hidalgo Calleja², Esther Toledano Martinez³ and Carlos Montilla Morales², ¹Hospital Universitario Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: To evaluate the quality of sleep in patients with psoriatic arthritis (PsA) and its relationship with/to clinical variables, activity, functionality, the impact of the…
Abstract Number: 0755 • ACR Convergence 2022
Immune Responses and Disease Marker Changes Following SARS-CoV-2 mRNA Vaccination in a Cohort of Rheumatic Disease Patients
Zesheng An¹, Xian Zhou¹, Yanfeng Li¹, Jane Jaquith¹, Kathleen McCarthy-Fruin¹, Kenneth J. Warrington¹, Ali Duarte-Garcia¹, Uma Thanarajasingam¹, Cornelia M. Weyand² and Hu Zeng¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic School of Medicine, Rochester, MN, and Stanford University, Stanford, CA
Background/Purpose: The immunological responses following 3 doses of SARS-CoV2 mRNA vaccination in rheumatic disease patients are unclear. Furthermore, the impact of SARS-CoV2 mRNA vaccination on…
Abstract Number: 1024 • ACR Convergence 2022
Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Projection Based on Data from 65 Million People in the German Statutory Health Insurance
Philipp Sewerin¹, stephanie Knippschild², Sabrina Tulka², Xenofon Baraliakos³ and Ralph Brinks², ¹Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ²Chair for Medical Biometry and Epidemiology, Witten, Germany, ³Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Recently, we have reported an increase in the incidence and prevalence of patients with PsA in Germany based on claim data from 65 million…
Abstract Number: 1150 • ACR Convergence 2022
Spatial Transcriptomics Stratifies Health and Psoriatic Disease Severity by Emergent Cellular Ecosystems
Rochelle Castillo¹, Ikjot Sidhu¹, Igor Dolgalev¹, Ipsita Subudhi¹, Di Yan¹, Piotr Konieczny¹, Brandon Hsieh¹, Tinyi Chu², Rebecca Haberman¹, Shanmugapriya Selvaraj¹, Tomoe Shiomi¹, Rhina Medina¹, Parvathy Vasudevanpillai Girija¹, Adriana Heguy¹, Cynthia Loomis¹, Luis Chiriboga¹, Shane Meehan¹, Christopher Ritchlin³, Maria de la Luz Garcia-Hernandez⁴, John Carucci¹, Andrea Neimann¹, Shruti Naik¹ and Jose Scher⁵, ¹NYU Langone Health, New York, NY, ²Memorial Sloan Kettering Cancer Center, New York, NY, ³Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁴University of Rochester, West Henrietta, NY, ⁵New York University School of Medicine, New York, NY
Background/Purpose: The skin is recognized as a window into the immunopathogenic mechanisms driving the vast phenotypic spectrum of psoriatic disease.Methods: To better decipher the cellular…
Abstract Number: 1425 • ACR Convergence 2022
Treatment Persistence and Switching Patterns of ABP 501 (AMGEVITA®) in German Patients with Rheumatic Diseases
Ran Jin¹, Silvia Kruppert², Florian Scholz², Marc Hammer², Greg Kricorian¹, David Collier³ and Jonathan Kay⁴, ¹Amgen, Inc., Thousand Oaks, CA, ²IQVIA, Frankfurt, Germany, ³Amgen Inc., Simi Valley, CA, ⁴Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA
Background/Purpose: ABP 501 is the first adalimumab (ADA) biosimilar approved by the European Medical Association and the Food and Drug Administration for the treatment of…
Abstract Number: 1506 • ACR Convergence 2022
Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Population-Based Study
Paras Karmacharya¹, Rikesh Chakradhar², Alexis Ogdie³, John Davis⁴, Tina Gunderson⁴, Cassondra Hulshizer⁴, Kerry Wright⁴, Megha M. Tollefson⁵, Ali Duarte-Garcia⁴, Delamo Bekele⁴, Hilal Maradit Kremers⁴, Floranne Ernste⁴ and Cynthia Crowson⁶, ¹Vanderbilt University, Nashville, TN, ²St. Christopher's Hospital, Philadelphia, ³Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Rochester, ⁶Mayo Clinic, Eyota, MN
Background/Purpose: Psoriasis is a systemic inflammatory disorder associated with cardiometabolic and other comorbidities. Psoriasis frequently precedes development of psoriatic arthritis (PsA), and comorbidities in psoriasis…
Abstract Number: 1768 • ACR Convergence 2022
Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study
Sanjana Tarannum¹, Jessica Widdifield¹, C. Fangyun Wang², Sindhu R. Johnson³, Paula Rochon¹ and Lihi Eder⁴, ¹University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Delayed diagnosis of inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), is associated with joint damage and disability.…
Abstract Number: 2120 • ACR Convergence 2022
Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of 11 Phase 2/3 Clinical Studies in Psoriasis and Psoriatic Arthritis
Bruce Strober¹, Laura Coates², Jenny Yu³, Katelyn Rowland⁴, Evan Leibowitz⁴, Megan Miller⁵, Alexa Kollmeier⁶, Shu Li⁵, Yanli Wang⁵, Daphne Chan⁴, Soumya Chakravarty⁷, Ya-Wen Yang⁸, May Shawi⁸, Mark Lebwohl⁹ and Proton Rahman¹⁰, ¹Yale University, New Haven, CT; Central Connecticut Dermatology Research, Cromwell, CT, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, USA, San Diego, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Spring House, PA/San Diego, Spring House, PA/San Diego, CA, ⁶Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁷Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁸Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰Memorial University, St. John's, NL, Canada
Background/Purpose: Guselkumab (GUS) is a fully human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23, inhibiting its function. GUS has been shown…
Abstract Number: 2137 • ACR Convergence 2022
Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis
Lihi Eder¹, Laura Coates², Peter Nash³, Uta Kiltz⁴, Ennio Lubrano⁵, Erin McDearmon-Blondell⁶, Tianming Gao⁷ and Alexis Ogdie⁸, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, ⁶AbbVie, Inc., Mettawa, IL, ⁷AbbVie, Inc., North Chicago, IL, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Evidence suggests that response to treatment in PsA may vary with patient (pt) characteristics, such as sex.1 This post hoc analysis of the Phase…
Abstract Number: 2199 • ACR Convergence 2022
Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data
Jeffrey Curtis¹, Yujie Su², Cassie Clinton², Patrick Stewart³, Bryant England⁴, Tim Buekelman⁵ and Fenglong Xie², ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Bendcare, Boca Raton, FL, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵FASTER, Hoover, AL
Background/Purpose: Many patients with autoimmune and inflammatory conditions discontinue biologics and other immunomodulatory medications prematurely, but many fail to even start (primary non-adherence). We examined…
Abstract Number: 0062 • ACR Convergence 2022
Comparing Alzheimer’s Disease Risk in Patients with Chronic Inflammatory Autoimmune Diseases: A Medicare Cohort Study
Justin Levinson¹, Jonathan Katz², Yi Chen³, W. Ryan Powell⁴, Andrea Gilmore-Bykovskyi⁵, Amy J. Kind⁶ and Christie Bartels⁷, ¹University of Wisconsin School of Medicine and Public Health, Department of Medicine, Rheumatology Division, Madison, WI, ²University of Wisconsin Hospitals and Clinics, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Department of Medicine, Department of Biostatistics and Informatics, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Center for Health Disparities Research, Thousand Oaks, CA, ⁵University of Wisconsin School of Medicine and Public Health, Department of Emergency Medicine; and the Center for Health Disparities Research, Madison, WI, ⁶University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division & Center for Health Disparities Research, Madison, WI, ⁷University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Chronic inflammatory diseases have been associated with an increased risk of Alzheimer’s disease (AD), yet emerging research in rheumatoid arthritis (RA) and psoriasis suggests…
Abstract Number: 0389 • ACR Convergence 2022
Vaccine Effectiveness Among Patients with Psoriatic Disease: A Population-based Study
Lihi Eder¹, Idit Lavi², Amir Haddad³, Nili Stein⁴, Ilan feldhamer⁵, ARNON DOV COHEN⁵, Walid Saliba² and Devy Zisman², ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Carmel Medical Center, Haifa, Israel, ³Carmel Medical Centre, Haifa, Israel, ⁴Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel, ⁵Clalit Health Services, Tel Aviv, Israel
Background/Purpose: We assess the effectiveness of COVID-19 vaccination in preventing SARS-CoV2 infection and COVID-19 hospitalizations in patients with psoriatic disease (PsD) and non-psoriatic controls, and…
Abstract Number: 0757 • ACR Convergence 2022
Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases
Pankti Reid¹, Sabina Sandigursky², Maria A. Lopez-Olivo³, Juhee Song⁴, Houssein Safa⁵, Samuel Cytryn⁶, Maryam Buni⁷, Anna Pavlick⁸, Michelle Krogsgaard, PhD⁹, Osama Abu-Shawer¹⁰, Mehmet Altan¹¹, Jeffrey Weber¹², Maria Suarez-Almazor¹³, Adi Diab¹⁴ and Noha Abdel-Wahab¹⁴, ¹University of Chicago Medical Center, Chicago, IL, ²NYU Langone Health, New York, NY, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas MD Anderson Cancer Center, Houston, TX, ⁵Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, ⁶Memorial Sloan Kettering Cancer Center, New York, NY, ⁷MD Anderson Cancer Center, Bellaire, TX, ⁸Medical Oncology, Weill Cornell Medical Center, New York, NY, ⁹Perlmutter Cancer Center, Department of Pathology, NYU Langone Health, New York, NY, ¹⁰Cleveland Clinic Foundation, Cleveland, OH, ¹¹Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, ¹²NYU Langone Medical Center, Laura and Isaac Perlmutter Cancer Center, New York, NY, ¹³MD Anderson Cancer Center, Houston, TX, ¹⁴UT MD Anderson Cancer Center, Houston, TX
Background/Purpose: Treatment with a combination of immune checkpoint inhibitors (ICI) has promising outcomes in many tumor types but carries higher adverse event risk than ICI…

1
2
3
…
60
Next Page »